- Home
- BCSF vs VALN Comparison
BCSF vs VALN Comparison
Compare BCSF & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | VALN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.8M | 875.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCSF | VALN |
|---|---|---|
| Price | $12.08 | $6.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $14.00 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 574.3K | 82.6K |
| Earning Date | 05-04-2026 | 03-18-2026 |
| Dividend Yield | ★ 15.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $5.43 |
| 52 Week High | $16.82 | $12.25 |
Technical Indicators
Market Signals| Indicator | BCSF | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 25.09 |
| Support Level | $11.82 | $5.69 |
| Resistance Level | $14.53 | $6.73 |
| Average True Range (ATR) | 0.30 | 0.42 |
| MACD | 0.01 | -0.57 |
| Stochastic Oscillator | 30.27 | 0.00 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.